認知症治療薬 - 世界市場の考察、競合情勢、市場予測（2030年）

世界の認知症治療薬の市場規模は、2023年に154億2,000万米ドル、2030年までに250億2,000万米ドルに達し、2024年～2030年の予測期間にCAGRで8.42％の成長が見込まれます。市場の成長は主に、認知症を発症しやすい老年人口の増加、慢性疾患の有病率の上昇、研究開発活動を促進するための政府による医療支出の増加、パイプライン段階にあり予測期間に承認される可能性のある薬剤の増加に起因します。さらに、医療とITの統合の進行や、認知症治療薬の開発を促進するための主要企業各社のさまざまな事業政策、提携、パートナーシップの利用可能性の向上が、予測期間における市場の促進要因となっています。

認知症治療薬の市場力学

認知症治療薬市場は、アルツハイマー病の患者数の増加により、現在成長を示しています。例えば、Alzeihmer's Disease Internationalが発表したデータによると、2020年に全世界で5,500万人以上が認知症を患っています。同資料によれば、この数は20年ごとに倍増し、2030年までに約7,800万人、2050年までに約1億3,900万人に達すると推定されています。

また、上記の資料によれば、もっとも急速に成長しているのは中国、インド、そして南アジアや西太平洋の近隣諸国です。

また、老年人口は認知症を発症しやすいため、老年人口の増加も認知症治療薬の需要を増加させます。例えば、Alzeihmer Europe organization（2022）によると、2020年にEU人口の5分の1超が65歳以上となり、2010年と比較して3％増加します。

さらに、科学者たちはより効果的な認知症治療薬を開発するため、現在も研究を続けています。認知症治療薬は、一時的な記憶喪失、思考や推論の問題、日常生活の機能低下を管理するうえで効果的な戦略の1つです。

したがって、前述のすべての要因が予測期間に世界の認知症治療薬市場を促進することが見込まれます。

しかし、医薬品の承認に関連する政府の厳しい規制や研究開発活動に関連する高いコストは、認知症治療薬市場の成長を抑制する可能性の高い要因です。

COVID-19パンデミックによる大流行は、認知症市場に大きな影響を与えることが判明しています。SARS-CoV-2感染症と認知症には、併存疾患からなる共通の危険因子があり、認知症患者は特に感染に脆弱であることが判明しました。さらに、ロックダウンは認知症患者の診断やケアの提供にさまざまな悪影響を及ぼし、患者の肉体的・精神的なウェルビーイングにさらなる負担をかける結果にもなっています。これとは別に、COVID-19は世界中の医療制度と社会的ケア制度の両方にかつてない圧力をかけ、認知症を患う人々とその家族介護者へのサービスとサポートの低下を引き起こしていました。

さらに、認知症向けのさまざまな製品の承認も、パンデミック中、認知症治療薬市場を推進してきました。例えば、2022年6月7日、食品医薬品局（FDA）はアルツァイマー病治療薬（アドヘルム/アドカヌマブ）に迅速医薬品承認を与えました。

認知症治療薬市場のセグメント分析

認知症治療薬市場の薬剤クラスセグメントでは、2024年～2030年の予測期間にMAO阻害薬サブセグメントが大きな市場シェアを占める見込みです。これは、モノアミン酸化酵素阻害薬が提供するさまざまな技術の進歩のためです。モノアミン酸化酵素阻害薬（MAOI）は、セロトニン、ドーパミン、ノルエピネフリンといった複数の脳内化学物質の分解を防ぐことによってうつ病の治療に役立つ、非常に強力な抗うつ薬の一種です。これは、個人の気分を調整するのに役立ちます。さらに、イソカルボキサジド（Marplan）、フェネルジン（Nardil）、セレギリン（Emsam）、トラニルシプロミン（Parnate）など、食品医薬品局（FDA）から認知症治療薬として承認されているモノアミン酸化酵素阻害薬もあります。

当レポートでは、世界の認知症治療薬市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 認知症治療薬市場レポートのイントロダクション

第2章 認知症治療薬市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価
• 財務ベンチマーク

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 認知症治療薬市場の主な要因の分析

• 認知症治療薬市場の促進要因
• 認知症治療薬市場の抑制要因と課題
• 認知症治療薬市場の機会

第5章 認知症治療薬のポーターのファイブフォース分析

第6章 認知症治療薬市場に対するCOVID-19の影響分析

第7章 認知症治療薬市場のレイアウト

• 薬剤クラス別
  • MAO阻害薬
  • グルタミン酸阻害薬
  • コリンエステラーゼ阻害薬
• 適応症別
  • レビー小体型認知症
  • パーキンソン病認知症
  • アルツハイマー病
  • 血管性認知症
  • その他
• 流通チャネル別
  • 小売薬局
  • 病院薬局
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 認知症治療薬：世界の企業シェア分析 - 主要3～5社

第9章 認知症治療薬の企業と製品のプロファイル

• Apotex Inc
• Aurobindo Pharma
• Eisai Co., Ltd
• Eli Lilly and Company
• Johnson and Johnson
• Pfizer, Inc.
• Teva Pharmaceuticals
• Zydus Cadila
• Janssen Pharmaceuticals, Inc.
• Biogen Pharmaceuticals
• Forest Laboratories, Inc.
• Novartis AG
• Sanofi S.A.
• AstraZeneca
• F. Hoffmann-La Roche
• Merck and Co.
• Valeant Pharmaceutical International
• Eisai, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Dementia drugs Market
• Table 3: Dementia drugs Market Analysis in Global (2021-2030)
• Table 4: Dementia drugs Market Analysis in Global by Drug Class (2021-2030)
• Table 5: Dementia drugs Market Analysis in Global by Indication (2021-2030)
• Table 6: Dementia drugs Market Analysis in Global by Distribution Channel (2021-2030)
• Table 7: Dementia drugs Market Analysis in North America (2021-2030)
• Table 8: Dementia drugs Market Analysis in North America by Drug Class (2021-2030)
• Table 9: Dementia drugs Market Analysis in North America by Indication (2021-2030)
• Table 10: Dementia drugs Market Analysis in North America by Distribution Channel (2021-2030)
• Table 11: Dementia drugs Market Analysis in North America by Country (2021-2030)
• Table 12: Dementia drugs Market Analysis in the US (2021-2030)
• Table 13: Dementia drugs Market Analysis in Canada (2021-2030)
• Table 14: Dementia drugs Market Analysis in Mexico (2021-2030)
• Table 15: Dementia drugs Market Analysis in Europe (2021-2030)
• Table 16: Dementia drugs Market Analysis in Europe by Drug Class (2021-2030)
• Table 17: Dementia drugs Market Analysis in Europe by Indication (2021-2030)
• Table 18: Dementia drugs Market Analysis in Europe by Distribution Channel (2021-2030)
• Table 19: Dementia drugs Market Analysis in Europe by Country (2021-2030)
• Table 20: Dementia drugs Market Analysis in France (2021-2030)
• Table 21: Dementia drugs Market Analysis in Germany (2021-2030)
• Table 22: Dementia drugs Market Analysis in the UK (2021-2030)
• Table 23: Dementia drugs Market Analysis in Italy (2021-2030)
• Table 24: Dementia drugs Market Analysis in Spain (2021-2030)
• Table 25: Dementia drugs Market Analysis in Russia (2021-2030)
• Table 26: Dementia drugs Market Analysis in Rest of Europe (2021-2030)
• Table 27: Dementia drugs Market Analysis in Asia-Pacific (2021-2030)
• Table 28: Dementia drugs Market Analysis in Asia-Pacific by Drug Class (2021-2030)
• Table 29: Dementia drugs Market Analysis in Asia-Pacific by Indication (2021-2030)
• Table 30: Dementia drugs Market Analysis in Asia-Pacific by Distribution Channel (2021-2030)
• Table 31: Dementia drugs Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 32: Dementia drugs Market Analysis in China (2021-2030)
• Table 33: Dementia drugs Market Analysis in Japan (2021-2030)
• Table 34: Dementia drugs Market Analysis in India (2021-2030)
• Table 35: Dementia drugs Market Analysis in Australia (2021-2030)
• Table 36: Dementia drugs Market Analysis in South Korea (2021-2030)
• Table 37: Dementia drugs Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 38: Dementia drugs Market Analysis in Rest of Asia-Pacific (2021-2030)
• Table 39: Dementia drugs Market Analysis in Rest of World (2021-2030)
• Table 40: Dementia drugs Market Analysis in Rest of World by Drug Class (2021-2030)
• Table 41: Dementia drugs Market Analysis in Rest of World by Indication (2021-2030)
• Table 42: Dementia drugs Market Analysis in Rest of World by Distribution Channel (2021-2030)
• Table 43: Dementia drugs Market Analysis in Rest of World by Country (2021-2030)
• Table 44: Dementia drugs Market Analysis in the Middle East (2021-2030)
• Table 45: Dementia drugs Market Analysis in Africa (2021-2030)
• Table 46: Dementia drugs Market Analysis in South America (2021-2030)
• Table 47: Dementia drugs Market Analysis in Rest of World by Country (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Dementia drugs Market
• Figure 3: Dementia drugs Market Analysis in Global (2021-2030)
• Figure 4: Dementia drugs Market Analysis in Global by Drug Class (2021-2030)
• Figure 5: Dementia drugs Market Analysis in Global by Indication (2021-2030)
• Figure 6: Dementia drugs Market Analysis in Global by Distribution Channel (2021-2030)
• Figure 7: Dementia drugs Market Analysis in North America (2021-2030)
• Figure 8: Dementia drugs Market Analysis in North America by Drug Class (2021-2030)
• Figure 9: Dementia drugs Market Analysis in North America by Indication (2021-2030)
• Figure 10: Dementia drugs Market Analysis in North America by Distribution Channel (2021-2030)
• Figure 11: Dementia drugs Market Analysis in North America by Country (2021-2030)
• Figure 12: Dementia drugs Market Analysis in the US (2021-2030)
• Figure 13: Dementia drugs Market Analysis in Canada (2021-2030)
• Figure 14: Dementia drugs Market Analysis in Mexico (2021-2030)
• Figure 15: Dementia drugs Market Analysis in Europe (2021-2030)
• Figure 16: Dementia drugs Market Analysis in Europe by Drug Class (2021-2030)
• Figure 17: Dementia drugs Market Analysis in Europe by Indication (2021-2030)
• Figure 18: Dementia drugs Market Analysis in Europe by Distribution Channel (2021-2030)
• Figure 19: Dementia drugs Market Analysis in Europe by Country (2021-2030)
• Figure 20: Dementia drugs Market Analysis in France (2021-2030)
• Figure 21: Dementia drugs Market Analysis in Germany (2021-2030)
• Figure 22: Dementia drugs Market Analysis in the UK (2021-2030)
• Figure 23: Dementia drugs Market Analysis in Italy (2021-2030)
• Figure 24: Dementia drugs Market Analysis in Spain (2021-2030)
• Figure 25: Dementia drugs Market Analysis in Russia (2021-2030)
• Figure 26: Dementia drugs Market Analysis in Rest of Europe (2021-2030)
• Figure 27: Dementia drugs Market Analysis in Asia-Pacific (2021-2030)
• Figure 28: Dementia drugs Market Analysis in Asia-Pacific by Drug Class (2021-2030)
• Figure 29: Dementia drugs Market Analysis in Asia-Pacific by Indication (2021-2030)
• Figure 30: Dementia drugs Market Analysis in Asia-Pacific by Distribution Channel (2021-2030)
• Figure 31: Dementia drugs Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 32: Dementia drugs Market Analysis in China (2021-2030)
• Figure 33: Dementia drugs Market Analysis in Japan (2021-2030)
• Figure 34: Dementia drugs Market Analysis in India (2021-2030)
• Figure 35: Dementia drugs Market Analysis in Australia (2021-2030)
• Figure 36: Dementia drugs Market Analysis in South Korea (2021-2030)
• Figure 37: Dementia drugs Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 38: Dementia drugs Market Analysis in Rest of Asia-Pacific (2021-2030)
• Figure 39: Dementia drugs Market Analysis in Rest of World (2021-2030)
• Figure 40: Dementia drugs Market Analysis in Rest of World by Drug Class (2021-2030)
• Figure 41: Dementia drugs Market Analysis in Rest of World by Indication (2021-2030)
• Figure 42: Dementia drugs Market Analysis in Rest of World by Distribution Channel (2021-2030)
• Figure 43: Dementia drugs Market Analysis in Rest of World by Country (2021-2030)
• Figure 44: Dementia drugs Market Analysis in the Middle East (2021-2030)
• Figure 45: Dementia drugs Market Analysis in Africa (2021-2030)
• Figure 46: Dementia drugs Market Analysis in South America (2021-2030)
• Figure 47: Dementia drugs Market Analysis in Rest of World by Country (2021-2030)

Dementia Drugs Market By Drug Class (Mao Inhibitors, Glutamate Inhibitors, And Cholinesterase Inhibitors), Indication (Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia, And Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, And Others), by geography, is projected to grow at a significant CAGR forecast till 2030 owing to the rising prevalence of dementia and the introduction of new and innovative technologies and drugs

The Global dementia drugs market was valued at USD 15.42 Billion in 2023, growing at a CAGR of 8.42% during the forecast period from 2024 to 2030, to reach USD 25.02 Billion by 2030. The rise in the dementia drugs market is predominantly attributed to the rising prevalence of geriatric population prone to developing dementia, the rising prevalence of chronic diseases, rising healthcare expenditure by the government for promoting research and development activities, rising number of drugs that are in the pipeline stage and can be approved during the forcasting period. Moreover, the rising integration of healthcare and IT, and the rising availability of different business policies, collaborations, and partnerships amongst the key players inorder to facilitate dementia drug development, among others are some of the factors responsible for driving the global dementia drugs market during the forecasted period.

Dementia Drugs Market Dynamics:

The dementia drugs market is witnessing growth at present owing to the rise in the number of patients suffering from Alzeihmer's Disease. For instance, according to the data published by the Alzeihmer's Disease International, in the year 2020, more than 55 million people were suffering from dementia globally. According to the same source, the number can be estimated to double evevry 20 years, thereby reaching to about 78 million patients by the year 2030 and about 139 million patients by the year 2050.

Also, as per the above mentioned source, the fastest growth is taking place in China, India, and their South-Asian and Western Pacific neighbours.

Also, an increasing prevalence of geriatric population will also increase the demand for dementia drugs, as geriatric population is prone to developing dementia. For instance, as per the Alzeihmer Europe organization 2022, more than one fifth of the EU population was aged 65 or over in 2020, which represents an increase of 3% compared to 2010.

Additionally, there is still ongoing research wherein scientists are trying harder for developing more effective dementia related drugs. Dementia drugs are one of the effective strategy in temporarily managing memory loss, thinking as well as reasoning probblems and day-to day functions.

Hence, all the aforementioned factors are anticipated to boost the global dementia drugs market during the forecasted period.

However, the strict government regulations related to drugs approval and the high cost associated with research and development activities are some of the factors likely to impede the dementia drugs market growth.

The outbreak caused by the COVID-19 pandemic is found to have a profound impact on the dementia market. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and dementia share some common risk factors comprising of co-morbidities, and patients living with dmenetia were found to be particularly vulnerable to the infection. Additionally, the lockdown measures have also led to various adverse disruptions to the diagnosis and delivery of care for patients suffering from dementia, and result in further strains on physical and mental well-being of the patients. Apart from this, COVID-19 had also placed an unprecedented pressure on both the health as well as the social care systes across the world, in turn causing reduction in services and support for people suffering from dementia and their family carers.

Furthermore, the approval of the various product for dementia has also propelled the dementia drugs market during the pandemic. For instance, on June 07, 2022, the Food and Drug Administration (FDA) had granted the accelerated drug approval for Alzeihmer's drug (Aduhelm /aducanumab) for the treatment of Alzeihmer's disease.

Dementia Drugs Market Segment Analysis:

Dementia drugs Market By Drug Class (MAO Inhibitors, Glutamate Inhibitors, And Cholinesterase Inhibitors), Indication (Lewy Body Dementia, Parkinson's Disease Dementia, Alzheimer's Disease, Vascular Dementia, And Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, And Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the Dementia drugs market under the drug class segment, the MAO inhibitors sub-segment is expected to hold a significant market share during the forecasted period from 2024-2030. This is because of the various technological advancements that are offered by the Monoamine Oxidase Inhibitors. Monoamine oxidase inhibitors (MAOIs) are an extremely strong class of antidepressants that help in the treatment of depression by preventing the breakdown of several brain chemicals such as serotonin, dopamine, and norepinephrine. It helps in regulating the mood of an individual. Furthermore, various Monoamine oxidase inhibitors that have been approved by Food and Drug Administration comprise of Isocarboxazid (Marplan), Phenelzine (Nardil), Selegiline (Emsam) and Tranylcypromine (Parnate) for the treatment of dementia.

Apart from this, in the indications segment, the Alzeihmers Disease can be anticipated to hold the significant market share owing to the rising prevalence of Alzeihmers disease, rise in the number of dementia drug approval, and presence of extensive pipeline stage drugs for this indication. For instance, as per the Alzeihmer's Assocation 2022, an estimated 6.5 million Americans aged 65 years and older are living with the Alzeihmer' disease in the year 2023.

Moreover, there is a plethors of drugs that are in the development stage for Alzeihmers and are on the verge of getting approvals. For instance, on June 09, 2022, Aducanumab, from the company Biogen, had been approved by the US Food and Drug Administration (FDA) for the treatment of Alzeihmer's disease. Owing to a rise in the demential drugs receiving marketing approvals, there will be an increase in the demand of the dementia drugs leading to an increase in the overall dementia drugs market during the forecasting period from 2024-2030.

North America is expected to dominate the overall Dementia Drugs Market:

Among all the regions, North America is expected to occupy a major share in the overall dementia drugs market during the forecasted period. This domination is owing to the rising patient population in the region. Moreover, the rise in number of drug approvals granted to the key manufacturers as a treatment for dementia in the region, increasing government initiative and funding to various drug developmental projects associated with dementia, and the rise in the number of mergers, acquisitions and collaborations amongst dementia drug manufacturers in the region, among others are expected to drive the regional dementia drugs market in the forthcoming years.

The rise in the number ofaging population in the United States will also propel the dementia drugs market as the aged population is more prone to developing dementia. For instance, according to the data provided by the Alzeihmer's Association, 2022, the number of Americans ged 65 years or older can be projected to grow from 58 million in the year 2023 to 88 million by the year 2050.

Furthermore, several dementia associated drugs have received an expedited approval grant by the Food and Drug Administration (FDA) , causing an increase in the demand of the dementia drugs, leading to an overall increase in the dementia drugs market. For instance, on June 24, 2022, Lilly's donanemab had received the United States FDA Breakthrough Therapy Designation for treatment of Alzheimer's disease.

Thus, the interplay of all the above-mentioned factors is likely to propel the genomic market growth in the region during the forecasted period.

Dementia Drugs Market Key Players:

Some of the key market players operating in the Dementia drugs market include Apotex Inc, AstraZeneca, Aurobindo Pharma, Eisai Co., Ltd, Eli Lilly and Company, Johnson and Johnson, Pfizer, Inc., Teva Pharmaceuticals, Zydus Cadila, Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Novartis AG, Sanofi S.A., AstraZeneca, F. Hoffmann-La Roche, Merck and Co., Inc., and Valeant Pharmaceutical International and others.

Recent Developmental Activities in the Dementia Drugs Market:

On June 24, 2022, Lilly's donanemb had received the United States FDA's Beakthrough Therapy designation for the treatment of Alzeihmer's disease.

On June 07, 2022, Aducanumab had received the fast-tracked for approval from Food and Administration for the treatment of Alzheimer's disease (AD).

Key Takeaways from the Dementia Drugs Market Report Study

• Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Dementia drugs market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the Global Dementia drugs Market.
• Various opportunities available for the other competitor in the Dementia drugs Market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Dementia drugs market growth in the coming future?

Target Audience who can be benefited from the Dementia Drugs Market Report Study

• Dementia drugs providers
• Research organizations and consulting companies
• Dementia drugs-related organization, association, forum, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders in Dementia drugs
• Various End-users who want to know more about the Dementia drugs Market and the latest technological developments in the Dementia drugs market.

Frequently Asked Questions for the Dementia Drugs Market:

1. What is Dementia drugs?

Dementia is a form of chronic disorder which affects the Dementia drugs are drugs that are used for management of symptoms associated with the dementia disorder.

2. What is the market for Global Dementia drugs?

The Global dementia drugs market was valued at USD 15.42 Billion in 2023, growing at a CAGR of 8.42% during the forecast period from 2024 to 2030, to reach USD 25.02 Billion by 2030.

3. What are the drivers for Global Dementia drugs?

The major factor driving the demand for Dementia drugs is the rising prevalence of dementia. Moreover, the the rising prevalence of chronic diseases, rising healthcare expenditure by the government for promoting research and development activities, rising number of drugs that are in the pipeline stage and can be approved, among others are some of the factors responsible for driving the global dementia drugs market during the forecasted period.

4. What are the key players operating in Global Dementia drugs?

Some of the key market players operating in the Dementia drugs market include Apotex Inc, AstraZeneca, Aurobindo Pharma, Eisai Co., Ltd, Eli Lilly and Company, Johnson and Johnson, Pfizer, Inc., Teva Pharmaceuticals, Zydus Cadila, Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Novartis AG, Sanofi S.A., AstraZeneca, F. Hoffmann-La Roche, Merck and Co. Inc., and Valeant Pharmaceutical International and others.

5. Which region has the highest share in the Dementia drugs market?

Among all the regions, North America is expected to occupy a major share in the overall dementia drugs market during the forecasted period, 2024-2030. This domination is owing to the rising patient population suffering from dementia in the region. Moreover, rise in adoption of various dementia drugs by the key manufacturers to provide the better treatment solutions for dementia in the region, increasing government initiative and funding to various dementia development drugs, and regulatory approval of several dementia drugs in the region, among others are expected to drive the regional dementia drugs market in the forthcoming years.

Table of Contents

1.Dementia drugs Market Report Introduction

2.Dementia drugs Market Executive summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment
• 2.4. Financial Benchmarking

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Dementia drugs Market Key factors analysis

• 4.1. Dementia drugs Market Drivers
  • 4.1.1. The rising prevalence of patients suffering from dementia
  • 4.1.2. The rising government initiative to support the dementia drugs project
  • 4.1.3. Technological advancement and launches of Dementia drugs products
  • 4.1.4. Growing rise of geriatric population
• 4.2. Dementia drugs Market Restraints and Challenges
  • 4.2.1. High cost associated with the dementia drugs
  • 4.2.2. Strict government regulations related to dementia drugs
• 4.3. Dementia drugs Market Opportunities
  • 4.3.1. Rising integration of healthcare and IT inorder to boost demand in emerging economies
  • 4.3.2. Increase research funds for various dementia drugs

5. Dementia drugs Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Dementia drugs Market

7. Dementia drugs Market layout

• 7.1. By Drug Class
  • 7.1.1. MAO Inhibitors
  • 7.1.2. Glutamate Inhibitors
  • 7.1.3. Cholinesterase Inhibitors
• 7.2. By Indication
  • 7.2.1. Lewy Body Dementia
  • 7.2.2. Parkinson's Disease Dementia
  • 7.2.3. Alzheimer's Disease
  • 7.2.4. Vascular Dementia
  • 7.2.5. Others
• 7.3. By Distribution Channel
  • 7.3.1. Retail Pharmacies
  • 7.3.2. Hospital Pharmacies
  • 7.3.3. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. North America Dementia drugs Market, by Country
    • 7.4.1.1.1. United States
    • 7.4.1.1.2. Canada
    • 7.5.1.1.3. Mexico
  • 7.4.2. Europe
    • 7.4.2.1. Europe Dementia drugs Market, by Country
    • 7.4.2.1.1. France
    • 7.4.2.1.2. Germany
    • 7.4.2.1.3. United Kingdom
    • 7.4.2.1.4. Italy
    • 7.4.2.1.5. Spain
    • 7.4.2.1.6. Russia
    • 7.4.2.1.7. Rest of Europe
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. Asia-Pacific Dementia drugs Market, by Country
    • 7.4.3.1.1. China
    • 7.4.3.1.2. Japan
    • 7.4.3.1.3. India
    • 7.4.3.1.4. Australia
    • 7.4.3.1.5. South Korea
    • 7.4.3.1.6. Rest of Asia Pacific
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. RoW Dementia drugs Market, by Region
    • 7.4.4.1.1. Middle East
    • 7.4.4.1.2. Africa
    • 7.4.4.1.3. South America

8. Dementia drugs Global Company Share Analysis - Key 3-5 Companies

9. Dementia drugs Company and Product Profiles

• 9.1. Apotex Inc
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. Aurobindo Pharma
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. Eisai Co., Ltd
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. Eli Lilly and Company
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. Johnson and Johnson
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. Pfizer, Inc.
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. Teva Pharmaceuticals
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. Zydus Cadila
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. Janssen Pharmaceuticals, Inc.
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. Biogen Pharmaceuticals
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. Forest Laboratories, Inc.
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. Novartis AG
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. Sanofi S.A.
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. AstraZeneca
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. F. Hoffmann-La Roche
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16. Merck and Co.
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17. Valeant Pharmaceutical International
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18. Eisai, Inc.
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19. Eli Lilly and Company
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20. F. Hoffmann-La Roche
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us